Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2021
February 10, 2022 03:09 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated...
Sosei Group Corporation Proposes Changes to its Leadership Team as Part of Succession Plan to Drive the Company Through the Next Stage of its Evolution
February 01, 2022 05:12 ET
|
Sosei Group Corporation
Mr. Chris Cargill nominated for appointment as new Representative Executive Officer, President and Chief Executive OfficerMr. Shinichi Tamura will become Chairman of the Board, as a DirectorMs. Miwa...
Sosei Heptares Webinar Presentation for FY2021 Financial Results
January 21, 2022 05:29 ET
|
Sosei Group Corporation
TOKYO, Japan and CAMBRIDGE, United Kingdom, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights...
Sosei Heptares and Verily will collaborate to generate novel drug candidates against GPCR targets for immune-mediated diseases
January 06, 2022 05:07 ET
|
Sosei Group Corporation
Research agreement combines Verily’s proprietary Immune Profiler platform with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform and structure-based drug design capabilities ...
Sosei Heptares to present at 40th Annual J.P. Morgan Healthcare Conference
December 28, 2021 01:30 ET
|
Sosei Group Corporation
TOKYO, Japan and LONDON, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), today announced its Chief Financial Officer, Chris Cargill, will present at the 40th...
Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences
December 23, 2021 18:05 ET
|
Sosei Group Corporation
TOKYO, Japan and CAMBRIDGE, United Kingdom, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) today announces that in connection with the Collaboration and...
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR Targets
December 16, 2021 07:35 ET
|
Sosei Group Corporation
Collaboration aims to combine Twist’s proprietary synthetic antibody libraries and sophisticated bioinformatics expertise with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform to...